Funding for this research was provided by:
National Institutes of Health (U24HL154426)
Article History
Received: 26 February 2023
Accepted: 20 October 2023
First Online: 6 November 2023
Declarations
:
: Not applicable.
: Not applicable.
: MDH has received travel support from the American Heart Association and World Heart Federation and consulting fees from PwC Switzerland. MDH has an appointment at The George Institute for Global Health, which has a patent, license, and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. MDH has pending patents for heart failure polypills. EKT and EHG have no disclosures or financial conflicts of interest.